JDD May 2023 Issue Highlights | Special Focus: Skin Cancer
174541745417454
The May issue of the Journal of Drugs in Dermatology (JDD) focuses on skin cancer and includes the perfect blend of original articles and case reports. Topics include actinic keratosis versus squamous cell carcinoma, the utility of gene expression profiling in skin cancer, the prevalence of sunscreen use, and many more. Check out this month’s issue highlights straight from the JDD Editor’s …
The May issue of the Journal of Drugs in Dermatology (JDD) focuses on skin cancer and includes the perfect blend of original articles and case reports. Topics include actinic keratosis versus squamous cell carcinoma, the utility of gene expression profiling in skin cancer, the prevalence of sunscreen use, and many more. Check out this month’s issue highlights straight from the JDD Editor’s … Continue reading "JDD May 2023 Issue Highlights | Special Focus: Skin Cancer"
INTRODUCTION
Graham-Little-Piccardi-Lasseur Syndrome (GLPLS) is a rare clinical subtype of lichen planopilaris (LPP) that manifests as a triad of scarring alopecia of the scalp, nonscarring alopecia of the axillary and the pubic skin, and widespread lichenoid follicular papules.1 GLPLS more commonly affects women (male-to-female ratio ≃ 1:4), with the classic patient being a middle-aged Ca … 
The April issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, features, and case reports, with topics ranging from hormonal therapy in hidradenitis suppurativa, private equity in dermatology, vitiligo and its associated comorbidities, novel topical products for facial dyschromia, and many more. Check out this month’s issue highlights straight … 
The February issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and brief communications exploring topics such as efficacy and safety of 1% clascoterone cream in patients aged ≥12 years with acne vulgaris, dupilumab’s impact on atopic dermatitis among adolescent and adult patients, development and validation of a photonumeric scale … 
INTRODUCTION
Epoprostenol (Flolan) is a last-resort intravenous (IV) medication for the treatment of severe pulmonary arterial hypertension (PAH). Cutaneous adverse events of Flolan are well-known by pulmonologists, though lacking in dermatologic literature.1 We report an extensive near erythrodermic appearing asymptomatic eruption following long-term use of epoprostenol. This characteristic and … 